Modular Engineering of Lysostaphin with Significantly Improved Stability and Bioavailability for Treating MRSA Infections
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.4c18004 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Jingwei Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Intensive Care Unit, Children's Medical Center, The First Hospital of Jilin University, Changchun 130021, China. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Lysostaphin, Anti-Bacterial Agents, Staphylococcal Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Natural Science Foundation of Jilin Province, National Key Research and Development Program of China, Youth Innovation Promotion Association of the Chinese Academy of Sciences.
Abstract (Originalsprache)
Methicillin-resistant Staphylococcus aureus (MRSA) is a refractory pneumonia-causing pathogen due to the antibiotic resistance and the characteristics of persisting inside its host cell. Lysostaphin is a typical bacteriolytic enzyme for degrading bacterial cell walls via hydrolysis of pentaglycine cross-links, showing potential to combat multidrug-resistant bacteria. However, there are still grand challenges for native lysostaphin because of its poor shelf stability and limited bioavailability. To tackle these limitations, a modular assembly strategy is proposed to actively engineer the native lysostaphin, involving nanoassembly preparation via fusing with lysine-rich polypeptide. The engineered lysine component significantly improves the membrane-penetration capability of lysostaphin, greatly increasing its intracellular antibacterial activity by 12-fold compared to wild-type lysostaphin. Notably, the half-life of the nanoassembled lysostaphin is approximately 13 times longer than that of its native counterpart, greatly outperforming other studies. Most importantly, the shelf stability of our engineered lysostaphin is significantly improved, retaining over 99.9% of antibacterial activity after 12 weeks at room temperature. This modular assembly strategy successfully enhances the overall performance of lysostaphin, offering great promise for a platform technique to refine enzymatic material for widespread clinical demands.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Intensive Care Unit, Children's Medical Center, The First Hospital of Jilin University, Changchun 130021, China.
- State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China.
- Engineering Research Center of Advanced Rare Earth Materials (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing 100084, China.
- School of Biotechnology, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China.
- Xiangfu Laboratory, Jiaxing, Zhejiang 314102, China.
ORCID-Profile: Jiangchao Qian, Jingjing Li, Kai Liu, Fan Wang
Förderung
- Natural Science Foundation of Jilin Province
- National Key Research and Development Program of China
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Beijing Nova Program
- Xiangfu Lab Research Project
Zitieren
APA
Liu, J., Li, Y., Wang, S., Jia, B., Li, J., Qian, J., Li, J., Ma, C., Zhang, H., Liu, K., & Wang, F. (2025). Modular Engineering of Lysostaphin with Significantly Improved Stability and Bioavailability for Treating MRSA Infections. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c18004
Vancouver
Liu J, Li Y, Wang S, Jia B, Li J, Qian J, et al. Modular Engineering of Lysostaphin with Significantly Improved Stability and Bioavailability for Treating MRSA Infections. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c18004
BibTeX
@article{Liu2025,
author = {Liu, Jingwei and Li, Yumei and Wang, Shuang and Jia, Bo and Li, Jiaxin and Qian, Jiangchao and Li, Jingjing and Ma, Chao and Zhang, Hongjie and Liu, Kai and Wang, Fan},
title = {Modular Engineering of Lysostaphin with Significantly Improved Stability and Bioavailability for Treating MRSA Infections},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.4c18004}
}
EUVIMED